Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

1(25.0%)

Phase 1

1(25.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 3(1)

Phase 1(1)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT05675319Phase 3Terminated

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Role: collaborator

NCT04232241Phase 2Active Not Recruiting

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Role: collaborator

NCT05389319Phase 1Suspended

A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults

Role: collaborator

NCT03593161Not ApplicableUnknown

Humor Therapy and Distress After Allogeneic Stem Cell Transplantation

Role: collaborator

All 4 trials loaded